Poniard Pharmaceuticals, Inc. (PARD)
Stock Price:
$0.0460 USD
-0.0084 (-15.44%)
Updated Oct 23, 2020 2:47 PM EDT - Market closed
Key Info
| Market Cap |
68,936 |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-16.23M |
| Shares Out |
1.50M |
| EPS (ttm) |
-3.79 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$0.0460 |
| Previous Close |
$0.0544 |
| Change ($) |
-0.0084 |
| Change (%) |
-15.44% |
| Day's Open |
0.0460 |
| Day's Range |
0.0460 - 0.0460 |
| Day's Volume |
125 |
| 52-Week Range |
0.0127 - 0.1 |
More Stats
| Market Cap |
68,936 |
| Enterprise Value |
n/a |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
1.50M |
| Float |
n/a |
| EPS (basic) |
n/a |
| EPS (diluted) |
-3.79 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
47,723 |
| Short Ratio |
2.56 |
| Short % of Float |
n/a |
| Beta |
1.43 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
0.10 |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
-16.23M |
| Free Cash Flow |
n/a |
| Net Cash |
n/a |
| Net Cash / Share |
n/a |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-46.03% |
| ROE |
-210.37% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
80.0
Current: $0.0460
High
80.0
Target: 80.00
*Average 12-month price target from 1 stock analysts.
Financial Overview
No financial data available for this stock yet.
Company Details
| Full Name |
Poniard Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
7 |
Stock Information
| Ticker Symbol |
PARD |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: PARD |
| IPO Date |
August 11, 1988 |
Description
Poniard Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.